|
Substance active |
tocilizumab |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
treatment of patients 50 years or older with active Giant Cell Arteritis who cannot be adequately treated with the current standard GC therapy. |
|
Public documents |
|
|
Dernière mise à jour |
03/05/2021 |
RoActemra
Last updated on 03/04/2024